Windtree Therapeutics
WINT
WINT was delisted on the 20th of August, 2025.
9 hedge funds and large institutions have $2.72M invested in Windtree Therapeutics in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
29% more funds holding
Funds holding: 7 → 9 (+2)
0% more ownership
Funds ownership: 0% → 0% (+0%)
10% less capital invested
Capital invested by funds: $3.02M → $2.72M (-$293K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$240K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$80K |
| 3 |
Renaissance Technologies
New York
|
+$80K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$11K |
WINT Hedge Fund Activity: Q4 2021 in Review
9 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Windtree Therapeutics (WINT) for Q4 2021, worth a combined $2.72M — down 9.7% from $3.02M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new WINT positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Two Sigma Advisers, opening a new position worth an estimated $240K. The largest seller was Northwestern Mutual Wealth Management, cutting an estimated $11K.
- 9 institutional investors held Windtree Therapeutics (WINT) as of Q4 2021, up from 7 in Q3 2021.
- Funds reported $2.72M of Windtree Therapeutics stock for Q4 2021, down 9.7% quarter-over-quarter.
- 2 funds opened new Windtree Therapeutics positions in Q4 2021 and 0 closed out, a net change of +2 holders.
- The largest Windtree Therapeutics buyer in Q4 2021 was Two Sigma Advisers, an estimated $240K added.
- The largest Windtree Therapeutics seller in Q4 2021 was Northwestern Mutual Wealth Management, an estimated $11K sold.
Based on aggregated 13F filings for Q4 2021.